Vitamin C and Copper: study protocols
16 study groups took Vitamin C together with Copper. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin C
16 study groups in 10 studies say how much Vitamin C participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 63% of 16 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg to 50 mg | 3 |
| 50 mg to 100 mg | 1 |
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 10 |
Dose per serving from research: Copper
10 study groups in 9 studies say how much Copper participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 70% of 10 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mcg to 500 mcg | 2 |
| 500 mcg to 1 mg | 1 |
| 1 mg to 2.5 mg | 7 |
Commonly used together
16 of 16 study groups took Vitamin C and Copper with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin E | 15 |
| Zinc | 15 |
| Beta-Carotene | 8 |
| Iron | 4 |
| Vitamin A | 4 |
| Selenium | 3 |
16 study groups
| Study | ||||
|---|---|---|---|---|
| Effects of fortified milk on morbidity in young children in north India: community based, randomised, double masked placebo controlled trial 2007 · fortified milk · Children aged 1–3 years in a peri-urban settlement in north India | 40.2 mg | 270 mcg | 1 year | 316 |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 500 mg | 2 mg | 8 years | — |
| Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren 2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified | 50 mg | 2 mg | 335 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 100 mg | 2 mg | — | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 500 mg | 2 mg | 9 years | — |
| Micronutrient fortified milk improves iron status, anemia and growth among children 1-4 years: a double masked, randomized, controlled trial 2010 · Micronutrient-fortified milk (MN group) · Children aged 1–4 years in India; many had anemia, iron deficiency, or growth faltering | 40.2 mg | 270 mcg | 1 year | 316 |
| Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year 2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years | 180 mg | 1 mg | 1 year | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel half-dose (single softgel) · Healthy adults aged 18–45 years, women and men | 226 mg | — | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel full-dose (two softgels) · Healthy adults aged 18–45 years, women and men | 452 mg | — | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men | 452 mg | — | 1 day | 15 |
| Lutein Complex Supplementation Increases Ocular Blood Flow Biomarkers in Healthy Subjects 2019 · lutein phytochemicals complex · Healthy women, mean age 36.8 ± 12.1 years | 500 mg | 2 mg | 3 weeks | 16 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration | 500 mg | 2 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 500 mg | 2 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 500 mg | — | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 500 mg | — | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene and with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 500 mg | — | 5 years | — |